Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987929 | 0.90 | PIM1 (0.33) | TP53MAPTTHRB | |
| SCHEMBL4153027 | 0.81 | MAPT (0.50) | TP53MAPTTHRBLMNASLC2A1 | |
| SCHEMBL12094442 | 0.78 | TP53 (0.36) | TP53MAPTTHRBLMNASLC2A1 | |
| SCHEMBL12092304 | 0.78 | TP53 (0.40) | TP53MAPTTHRBLMNA | |
| SCHEMBL17354599 | 0.76 | TP53 (0.35) | TP53MAPTTHRBLMNA | |
| SCHEMBL2996787 | 0.73 | MAPT (0.52) | TP53MAPTTHRBLMNA | |
| SCHEMBL2981865 | 0.72 | MAPT (0.42) | TP53MAPTTHRBLMNA | |
| SCHEMBL2992714 | 0.71 | MAPT (0.47) | TP53MAPTTHRBLMNA | |
| SCHEMBL17685231 | 0.70 | MAPT (0.41) | TP53MAPTTHRBLMNASLC2A1 | |
| SCHEMBL2995639 | 0.70 | MAPT (0.49) | TP53MAPTTHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970118-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2018-09-12 | — | — | EP | claimed |
| EP-2970118-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Manfredi, John (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014164222-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2014-10-09 | — | — | WO | claimed |
| EP-2970118-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2813498-B1 | Compounds for Alzheimer's disease | MANFREDI JOHN (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2970118-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Manfredi, John (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2813498-A1 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014164222-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | SLC18A2, SLC18A3, NLN | TP53 2751/4885MAPT 10/4885THRB 2651/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | TP53 306/4885MAPT 46/4885THRB 3789/4885 |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | PSEN2, PSEN1, CLN6 | TP53 253/4885MAPT 28/4885THRB 3292/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | TP53 578/4885MAPT 24/4885THRB 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.